Sort
48,018 grants matching “immunotherapy”
Genetic and molecular mechanisms of replication of araC damaged DNA
$391,297Satya Prakash · University Of Texas Med Br Galveston · R01 · FY2019 · CA
ILT3 (LILRB4) in anti-tumor immunity and immunotherapy
$391,277Marco Colonna · Washington University · R21 · FY2024 · CA
Targeting tumor innate immune signaling in pancreatic cancer
$391,277Kian H Lim · Washington University · R01 · FY2025 · CA
Identification of T Cell-Defined Antigens in Ovarian Cancer
$391,253Cassian Yee · Fred Hutchinson Cancer Research Center · R33 · FY2010 · CA
Chemical proteomic investigation of lipid kinase specificity and druggability
$391,252Ku-Lung Hsu · University Of Virginia · R01 · FY2023 · AI
Functional genetics of human innate immunity in the bimodal gamma delta T cell response to Epstein-Barr Virus and in education of NK cells and their re-education to respond to autologous cells
$391,250Peter R Parham · Stanford University · R01 · FY2020 · AI
Phase II Trial of Arimoclomol in IBM
$391,250Mazen Dimachkie · University Of Kansas Medical Center · R01 · FY2018 · FD
Functional genetics of human innate immunity in the bimodal gamma delta T cell response to Epstein-Barr Virus and in education of NK cells and their re-education to respond to autologous cells
$391,250Peter R Parham · Stanford University · R01 · FY2019 · AI
Functional genetics of human innate immunity in the bimodal gamma delta T cell response to Epstein-Barr Virus and in education of NK cells and their re-education to respond to autologous cells
$391,250Peter R Parham · Stanford University · R01 · FY2022 · AI
Functional genetics of human innate immunity in the bimodal gamma delta T cell response to Epstein-Barr Virus and in education of NK cells and their re-education to respond to autologous cells
$391,250Peter R Parham · Stanford University · R01 · FY2021 · AI
Macrophage-targeted lncRNA-regulating nanoparticles for glioblastoma treatment
$391,250Edjah Nduom · Emory University · R01 · FY2025 · NS
Functional genetics of human innate immunity in the bimodal gamma delta T cell response to Epstein-Barr Virus and in education of NK cells and their re-education to respond to autologous cells
$391,250Peter R Parham · Stanford University · R01 · FY2023 · AI
Macrophage-targeted lncRNA-regulating nanoparticles for glioblastoma treatment
$391,250Edjah Nduom · Emory University · R01 · FY2023 · NS
CANCER AND LEUKEMIA GROUP B
$391,239Dana-Farber Cancer Institute · U10 · FY2001 · CA
GENE EXPRESSION PROFILE OF PROGRESSION &RESPONSE IN CML
$391,215Fred Hutchinson Cancer Research Center · U01 · FY2002 · CA
Solid-state nanopores and silicon nanomembranes for ultrasensitive protein biomarker detection
$391,211James L McGrath · University Of Rochester · R01 · FY2024 · EB
Dual-pronged nano-drug delivery using plant virus-like particles
$391,196Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2022 · CA
Small Molecule Activators of Procaspases as Anti-Cancer Agents
$391,184Paul Hergenrother · University Of Illinois At Urbana-Champaign · R01 · FY2019 · CA
Role of KAT5 in lung cancer
$391,170Susumu Kobayashi · Beth Israel Deaconess Medical Center · R01 · FY2022 · CA
Role of KAT5 in lung cancer
$391,170Susumu Kobayashi · Beth Israel Deaconess Medical Center · R01 · FY2023 · CA
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma
$391,138Gregory B. Lesinski · Emory University · R01 · FY2018 · CA
Integration of neo-antigen vaccines and immune checkpoint therapy
$391,107Elizabeth Marion Jaffee · Johns Hopkins University · P01 · FY2025 · CA
Integration of neo-antigen vaccines and immune checkpoint therapy
$391,107Elizabeth Marion Jaffee · Johns Hopkins University · P01 · FY2021 · CA
The B7x pathways in the tumor microenvironment
$391,020Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2022 · CA
The B7x pathways in the tumor microenvironment
$391,020Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2023 · CA